I'm with you on this, aidoaido. BLT have said they will have...

I'm with you on this, aidoaido. BLT have said they will have reverted to "normal" reporting of trial results, meaning they won't report on a cohort at half-time. Well that's "normal" for larger biotechs with lots of stuff well advanced, where a single test is not crucial, but for a little biotech like BLT doing its first in-human test, it is just unrealistic. Given how important this is, I think it is simply unacceptable for management not to provide news whenever possible, in order to keep the market fully informed during these crucial early stages.